The Changes in Plasma Retinol-Binding Protein 4 Levels are Associated With Those of the Apolipoprotein B-Containing Lipoproteins During Dietary and Drug Treatment

Angiology ◽  
2011 ◽  
Vol 63 (1) ◽  
pp. 67-75 ◽  
Author(s):  
Georgios A. Christou ◽  
Constantinos C. Tellis ◽  
Moses S. Elisaf ◽  
Alexandros D. Tselepis ◽  
Dimitrios N. Kiortsis
Keyword(s):  
Apolipoprotein B ◽  
Binding Protein ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Retinol Binding Protein ◽  
Percentage Change ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Retinol Binding Protein 4

We investigated the association between retinol-binding protein 4 (RBP4) and apolipoprotein B (ApoB)-containing lipoproteins. Obese or overweight, hypertriglyceridemic patients underwent the following interventions for 3 months: (1) Diet (n = 20), (2) Diet + fenofibrate (n = 18), (3) Diet + rimonabant (n = 8). Circulating RBP4 decreased during dietary treatment. The percentage change in RBP4 was positively correlated with the percentage changes in very-low density lipoprotein cholesterol ( r = .570, P = .02), low-density lipoprotein cholesterol ([LDL-C]; r = .605, P = .01), ApoB ( r = .705, P = .007), and small dense LDL-C ([sdLDL-C]; r = .872, P < .001). The percentage change in RBP4 was the best predictor of the percentage changes in sdLDL-C and ApoB. Rimonabant treatment reduced RBP4, whereas fenofibrate increased RBP4 during the first month of therapy followed by a subsequent decrease. In conclusion, RBP4 may significantly influence the metabolic pathways responsible for changes in ApoB lipoprotein subspecies, thus RBP4 may be associated with cardiovascular disease risk.

scholarly journals Association of Retinol Binding Protein- 4 (RBP4) with Glycemia, Dyslipidemia, Hypertension, and Obesity in Type 2 Diabetic Iraqi Patients

2020 ◽  
Vol 29 (2) ◽  
pp. 263-270
Author(s):  
Thair L. Jabbar ◽  
Ali A. Kasim
Keyword(s):  
Diabetes Mellitus ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Retinol Binding Protein ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Retinol Binding Protein 4

Abstract: Background: Retinol binding protein 4 (RBP4), an adipokine that participate in a lipid metabolism or insulin resistance through a complex regulatory network. Recently, RBP4 was reported to be associated with many cardiovascular diseases (CVDs) risk factors in patients of type 2 diabetes mellitus (T2DM). This study aims to study the correlation of  serum RBP4 with some markers of glycemic control, dyslipidemia, hypertension and obesity in T2DM Iraqi patients. Subjects and Methods: one hundred fifty participants were enrolled in this coss-sectional study, 120 of participants were T2DM patients and 30 were apparently healthy individuals to serve as control group. Results: Serum RBP4 levels are higher in T2DM patients with poor glycemic control, dyslipedemia, hypertension, or obesity compared  to the control group. Serum RBP4 is positively correlated with body mass index, fasting blood glucose, glycosylated hemoglobin, systolic blood pressure (P<0.001), and plasma triacylglycerols, very low density lipoprotein cholesterol, and low density lipoprotein cholesterol (P<0.05) and negatively correlated with high density lipoprotein cholesterol (P<0.001). Conclusion: serum RBP4 is correlated with many risk factors of CVD in T2DM Iraqi patients.   keywords: RBP4, type 2 diabetes mellitus, dyslipidemia, hypertension, obesity

Abstract 5054: Apolipoprotein B, but not Low-Density Lipoprotein Cholesterol is Associated with Coronary Atherosclerosis Beyond Total Cholesterol in Diabetics and Non-Diabetics

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Seth S Martin ◽  
Atif N Qasim ◽  
Daniel J Rader ◽  
Muredach P Reilly
Keyword(s):  
Total Cholesterol ◽  
Apolipoprotein B ◽  
Coronary Atherosclerosis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Type 2 Diabetics

Introduction: Accumulating evidence suggests that apolipoprotein B (apoB) is superior to low-density lipoprotein cholesterol (LDL-C) in prediction of cardiovascular events. Yet, an important outstanding question is whether apoB, relative to LDL, is an enhanced marker for subclinical atherosclerosis, particularly in diabetics where LDL levels may underestimate atherogenic lipid burden due to increased proportion of small, dense LDL. Hypothesis: We hypothesized that plasma apoB would be a better predictor than LDL-C of coronary artery calcification (CAC) scores in type 2 diabetics and non-type 2 diabetics. Methods: We performed cross-sectional analyses of asymptomatic Caucasians in (1) The Study of Inherited Risk of Coronary Atherosclerosis (434 men and 383 women; median age 48, non-diabetics) and (2) The Penn Diabetes Heart Study (580 men and 261 women; median age 60, type 2 diabetics). Results: Levels of apoB and LDL-C were correlated in diabetics (r=0.78, p<0.001) and non-diabetics (r=0.77, p<0.001). There was no association between LDL-C and CAC in diabetics. In non-diabetics, an association of LDL-C was lost after adjustment for total cholesterol. In contrast, after controlling for age, gender, statin therapy, and total cholesterol, levels of apoB were positively associated with CAC in diabetics [tobit regression ratio for 30 mg/dl increase in apoB 2.94 (95% CI 1.62 – 5.53), p=0.001) and had a more modest association with CAC in non-diabetics [1.67 (95% CI 1.16 – 2.32), p=0.005]. Conclusions: ApoB, but not LDL-C, predicted CAC scores, a measure of coronary atherosclerotic burden. The strength of this association was greater in diabetics than non-diabetics. Relative to LDL-C, plasma apoB levels may be particularly useful in assessing CVD risk in type 2 diabetes.

scholarly journals Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Zaza Makaridze ◽  
Elene Giorgadze ◽  
Ketevan Asatiani
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Regression Models ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Apolipoprotein A ◽  
Multiple Regression Models

The study was designed to assess the association between insulin resistance (IR) and apolipoprotein B/apolipoprotein A-I ratio (ApoB/ApoA-I ratio), metabolic syndrome (MetS) components, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the nondiabetic population of Georgia. The subjects were 1522 Georgians of Caucasian origin (mean age = 45 years, 653 women) without diabetes who had visited the clinics for a related health checkup between 2012 and 2013. IR was calculated using the computer homeostasis model assessment (HOMA2-IR) and was defined as the upper quartile. MetS was diagnosed using the updated ATP-III definition of the metabolic syndrome. Logistic and multiple regression models were used to estimate the association between IR and other components. IR was positively correlated with age, ApoB, ApoB/ApoA-I ratio, MetS components (excluding high-density lipoprotein cholesterol—HDL-C), LDL-C, fasting insulin, and TC and negatively correlated with HDL-C and ApoA-I in both sexes (allP<0.001). In the logistic regression models, gender, age, ApoB/ApoA-I ratio, diastolic pressure, HDL-C, LDL-C, fasting glucose, and triglycerides were the covariates significantly associated with IR (OR: 8.64, 1.03, 17.95, 1.06, 0.13, 1.17, 3.75, and 2.29, resp.; allP<0.05). Multiple regression models demonstrated that these components (except for HDL-C) made an independent contribution to the prediction of HOMA2 (allP<0.05).

Sign in / Sign up

Export Citation Format

Share Document